Mackay Shields LLC purchased a new position in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 16,200 shares of the biotechnology company’s stock, valued at approximately $435,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. TD Asset Management Inc. raised its holdings in Aimmune Therapeutics by 2.4% during the 2nd quarter. TD Asset Management Inc. now owns 88,927 shares of the biotechnology company’s stock worth $2,391,000 after purchasing an additional 2,100 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Aimmune Therapeutics by 24.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 14,637 shares of the biotechnology company’s stock worth $466,000 after buying an additional 2,854 shares during the period. Janney Montgomery Scott LLC grew its position in shares of Aimmune Therapeutics by 27.8% during the 2nd quarter. Janney Montgomery Scott LLC now owns 14,720 shares of the biotechnology company’s stock worth $396,000 after buying an additional 3,200 shares during the period. Wells Fargo & Company MN grew its position in shares of Aimmune Therapeutics by 7.6% during the 1st quarter. Wells Fargo & Company MN now owns 67,954 shares of the biotechnology company’s stock worth $2,163,000 after buying an additional 4,796 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Aimmune Therapeutics by 55.2% during the 1st quarter. Legal & General Group Plc now owns 14,102 shares of the biotechnology company’s stock worth $449,000 after buying an additional 5,015 shares during the period. Hedge funds and other institutional investors own 78.16% of the company’s stock.

In related news, insider Stephen George Dilly sold 105,169 shares of Aimmune Therapeutics stock in a transaction on Friday, June 8th. The shares were sold at an average price of $30.92, for a total value of $3,251,825.48. Following the completion of the sale, the insider now owns 345,773 shares of the company’s stock, valued at approximately $10,691,301.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Eric Bjerkholt purchased 1,600 shares of Aimmune Therapeutics stock in a transaction that occurred on Wednesday, June 13th. The stock was acquired at an average cost of $30.41 per share, with a total value of $48,656.00. The disclosure for this purchase can be found here. In the last three months, insiders sold 300,000 shares of company stock valued at $9,475,105. 24.56% of the stock is currently owned by insiders.

Shares of AIMT stock opened at $28.01 on Friday. Aimmune Therapeutics Inc has a 52 week low of $20.49 and a 52 week high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.05). equities analysts forecast that Aimmune Therapeutics Inc will post -3.63 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Credit Suisse Group set a $47.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 10th. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 22nd. Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research report on Friday, May 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $72.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, May 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Aimmune Therapeutics presently has a consensus rating of “Buy” and an average target price of $52.89.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: Tariff

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.